Full Text
POSC31 Comparison of Atezolizumab, Nivolumab, and Pembrolizumab in Elderly Cancer Patients over 65 Years of Age

Abstract

Authors

S Min

Back to ISPOR Europe 2021 Abstracts: Emerging Frontiers and Opportunities
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×